Published in Int Rev Neurobiol on January 01, 2004
The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron (2007) 2.96
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry (2008) 1.55
Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiatry (2009) 1.53
Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet (2006) 1.50
Steady state responses: electrophysiological assessment of sensory function in schizophrenia. Schizophr Bull (2009) 1.33
Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci (2010) 1.13
N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) (2005) 1.11
Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Ther Clin Risk Manag (2014) 1.11
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity. J Neurosci (2009) 1.04
Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. J Physiol (2005) 1.04
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology (2011) 1.02
Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology (2005) 1.00
Mechanisms of neuregulin action. Novartis Found Symp (2008) 0.95
Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology (2009) 0.94
The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl) (2008) 0.93
Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience (2011) 0.92
The functional anatomy of schizophrenia: A dynamic causal modeling study of predictive coding. Schizophr Res (2014) 0.92
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding. Brain Res (2008) 0.90
Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest (2012) 0.87
Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. Neurotoxicology (2011) 0.86
Prenatal lead exposure and schizophrenia: a plausible neurobiologic connection. Environ Health Perspect (2004) 0.84
Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology (Berl) (2009) 0.84
Imaging genetics of structural brain connectivity and neural integrity markers. Neuroimage (2009) 0.83
Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia. Neuropsychopharmacology (2011) 0.83
Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem (2011) 0.83
Dynamics and function of distal regulatory elements during neurogenesis and neuroplasticity. Genome Res (2015) 0.83
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl Psychiatry (2015) 0.82
Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. Transl Psychiatry (2015) 0.79
Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats. J Neural Transm (Vienna) (2007) 0.78
A new treatment for cognitive disorders related to in utero exposure to alcohol. Neural Regen Res (2013) 0.78
Quantification of the novel N-methyl-d-aspartate receptor ligand [11C]GMOM in man. J Cereb Blood Flow Metab (2015) 0.78
Converging models of schizophrenia - Network alterations of prefrontal cortex underlying cognitive impairments. Prog Neurobiol (2015) 0.76
Theranostic Biomarkers for Schizophrenia. Int J Mol Sci (2017) 0.75
Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders. Int Rev Neurobiol (2015) 0.75
Additive effect of MTHFR and GRIN1 genetic polymorphisms on the risk of schizophrenia. Mol Biol Res Commun (2015) 0.75
Genome-wide methylation analysis of a large population sample shows neurological pathways involvement in chronic widespread musculoskeletal pain. Pain (2017) 0.75
Aberrant neural networks for the recognition memory of socially relevant information in patients with schizophrenia. Brain Behav (2016) 0.75
Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. Neurosci Biobehav Rev (2017) 0.75
Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI. Psychopharmacology (Berl) (2013) 0.75
Homer1a protein expression in schizophrenia, bipolar disorder, and major depression. J Neural Transm (Vienna) (2017) 0.75
Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci (2003) 2.43
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) (2003) 1.29
Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord (2002) 1.08
Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis. Biol Psychiatry (2004) 1.07
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry (2002) 1.06
Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. J Physiol (2005) 1.04
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) (2004) 1.01
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry (2006) 0.93
The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. Eur J Neurosci (2009) 0.89
Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry (2003) 0.86
Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse (2009) 0.81
Promoter analysis of human glutamate carboxypeptidase II. Brain Res (2007) 0.80
Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia. Schizophr Res (2004) 0.75